| CAS | 202463-00-1 |
| Sequence | Ac-His-D-Phe-Asp-Ala-Val-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Lys-Arg-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-NH2 |
| Sequence Single | Ac-HfDAVFTNSYRKVLKRLSARKLLQDIL-NH2 |
| Molecular Formula | C150H246N44O38 |
| Molecular Weight | 3273.88 |
| Synonyms | Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cancer Research |
| Description | PG 97-269 also called Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), is a selective high affinity VPAC1 receptor antagonist with negligible affinity for the PACAP type I receptor. The Ki values were 15 +/- 5 nM for the rat and 2 +/- 1 nM for the human VPAC1 receptors. PG 97-269 may be useful for the evaluation of the physiological role of VIP in rat and human tissues. |
| References | 1. 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. A.Kawabata et al., Br. J. Pharmacol., 144, 212 (2005) 2. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors. D.Cunha-Reis et al., Brain Res., 1049, 52 (2005) 3. Inhibitory pathways in the circular muscle of rat jejunum. G.Vanneste et al., Br. J. Pharmacol., 143, 107 (2004) 4. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. L.Dickson et al., Neuropharmacology, 51, 1086 (2006) |